Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
John A HeySusan AbushakraKaj BlennowEric M ReimanJakub HortNiels D PrinsKaterina SheardovaPatrick KesslakLarry ShenXinyi ZhuAdem AlbayrakJijo PaulJean F SchaeferAidan PowerMartin TolarPublished in: Drugs (2024)
https://clinicaltrials.gov/study/NCT04693520 .
Keyphrases
- open label
- cognitive decline
- white matter
- clinical trial
- mild cognitive impairment
- cerebral ischemia
- resting state
- high fat diet
- squamous cell carcinoma
- randomized controlled trial
- phase ii
- skeletal muscle
- multiple sclerosis
- type diabetes
- metabolic syndrome
- study protocol
- functional connectivity
- phase iii
- insulin resistance